🇪🇺 Trovert in European Union

EMA authorised Trovert on 12 November 2002

Marketing authorisations

EMA — authorised 12 November 2002

  • Application: EMEA/H/C/000409
  • Marketing authorisation holder: Pfizer Europe MA EEIG
  • Local brand name: Somavert
  • Indication: Treatment of adult patients with acromegaly who have had an inadequate response to surgery and/or radiation therapy and in whom an appropriate medical treatment with somatostatin analogues did not normalize IGF-I concentrations or was not tolerated. Treatment of adult patients with acromegaly who have had an inadequate response to surgery and/or radiation therapy and in whom an appropriate medical treatment with somatostatin analogues did not normalize IGF -I concentrations or was not tolerated.
  • Status: approved

Read official source →

EMA — authorised 13 November 2002

  • Status: approved

Trovert in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Other Oncology approved in European Union

Frequently asked questions

Is Trovert approved in European Union?

Yes. EMA authorised it on 12 November 2002; EMA authorised it on 13 November 2002.

Who is the marketing authorisation holder for Trovert in European Union?

Pfizer Europe MA EEIG holds the EU marketing authorisation.